SAT-163 Status at 10 Years: Long-Term Follow-Up for a Phase 2a Study of High-Specific-Activity (HSA) I 131 Iobenguane in Patients (Pts) with Relapsed/Refractory High-Risk Neuroblas...

por Villablanca, Judith G, Maris, John M, Stambler, Nancy, Zhou, Duo, DiPippo, Vincent A, Matthay, Katherine K
Publicado 2020

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study

por Kang, Min H, Villablanca, Judith G, Glade Bender, Julia L, Matthay, Katherine K, Groshen, Susan, Sposto, Richard, Czarnecki, Scarlett, Ames, Matthew M, Reynolds, C Patrick, Marachelian, Araz, Maurer, Barry J
Publicado 2014

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

por Goldsmith, Kelly C., Park, Julie R., Kayser, Kimberly, Malvar, Jemily, Chi, Yueh-Yun, Groshen, Susan G., Villablanca, Judith G., Krytska, Kateryna, Lai, Lillian M., Acharya, Patricia T., Goodarzian, Fariba, Pawel, Bruce, Shimada, Hiroyuki, Ghazarian, Susan, States, Lisa, Marshall, Lynley, Chesler, Louis, Granger, Meaghan, Desai, Ami V., Mody, Rajen, Morgenstern, Daniel A., Shusterman, Suzanne, Macy, Margaret E., Pinto, Navin, Schleiermacher, Gudrun, Vo, Kieuhoa, Thurm, Holger C., Chen, Joseph, Liyanage, Marlon, Peltz, Gerson, Matthay, Katherine K., Berko, Esther R., Maris, John M., Marachelian, Araz, Mossé, Yael P.
Publicado 2023